Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption

Document Type

Journal Article

Publication Date

8-1-2017

Journal

Journal of Virology

Volume

91

Issue

15

DOI

10.1128/JVI.00603-17

Keywords

ADCC; Analytical treatment interruption; HIV-1 cure; Latency; Latencyreversing agent; Panobinostat; SMART trial

Abstract

© 2017 American Society for Microbiology. There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on long-term antiretroviral therapy (ART) and may not be sufficient to eliminate reactivated latently infected cells. It is not known whether reactivation from latency with latency-reversing agents (LRAs) could provide sufficient antigenic stimulus to boost HIV-1-specific ADCC. We found that treatment with the LRA panobinostat or a short analytical treatment interruption (ATI), 21 to 59 days, was not sufficient to stimulate an increase in ADCC-competent antibodies, despite viral rebound in all subjects who underwent the short ATI. In contrast, a longer ATI, 2 to 12 months, among subjects enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) trial robustly boosted HIV-1 gp120-specific Fc receptor-binding antibodies and ADCC against HIV-1-infected cells in vitro. These results show that there is a lag between viral recrudescence and the boosting of ADCC antibodies, which has implications for strategies toward eliminating latently infected cells.

Link to Full Text

Share

COinS